Cellectar Biosciences (CLRB) Competitors $5.08 -0.20 (-3.79%) Closing price 04:00 PM EasternExtended Trading$5.19 +0.11 (+2.17%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLRB vs. MNOV, GANX, ABVC, IMMX, HOWL, BTAI, CLNN, CUE, DTIL, and DRRXShould you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include MediciNova (MNOV), Gain Therapeutics (GANX), ABVC BioPharma (ABVC), Immix Biopharma (IMMX), Werewolf Therapeutics (HOWL), BioXcel Therapeutics (BTAI), Clene (CLNN), Cue Biopharma (CUE), Precision BioSciences (DTIL), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry. Cellectar Biosciences vs. Its Competitors MediciNova Gain Therapeutics ABVC BioPharma Immix Biopharma Werewolf Therapeutics BioXcel Therapeutics Clene Cue Biopharma Precision BioSciences DURECT Cellectar Biosciences (NASDAQ:CLRB) and MediciNova (NASDAQ:MNOV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Is CLRB or MNOV more profitable? MediciNova's return on equity of -23.12% beat Cellectar Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cellectar BiosciencesN/A -486.67% -150.57% MediciNova N/A -23.12%-21.85% Do analysts rate CLRB or MNOV? Cellectar Biosciences currently has a consensus price target of $375.00, suggesting a potential upside of 7,281.89%. MediciNova has a consensus price target of $7.00, suggesting a potential upside of 469.11%. Given Cellectar Biosciences' higher possible upside, equities research analysts clearly believe Cellectar Biosciences is more favorable than MediciNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders & institutionals believe in CLRB or MNOV? 16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 5.0% of Cellectar Biosciences shares are held by insiders. Comparatively, 13.6% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to CLRB or MNOV? In the previous week, Cellectar Biosciences had 1 more articles in the media than MediciNova. MarketBeat recorded 5 mentions for Cellectar Biosciences and 4 mentions for MediciNova. MediciNova's average media sentiment score of 0.98 beat Cellectar Biosciences' score of 0.42 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, CLRB or MNOV? MediciNova has higher revenue and earnings than Cellectar Biosciences. MediciNova is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectar BiosciencesN/AN/A-$44.58M-$19.91-0.26MediciNova$1MN/A-$11.04M-$0.25-4.92 Which has more risk and volatility, CLRB or MNOV? Cellectar Biosciences has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. SummaryMediciNova beats Cellectar Biosciences on 9 of the 14 factors compared between the two stocks. Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLRB vs. The Competition Export to ExcelMetricCellectar BiosciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.85M$10.65B$5.79B$10.15BDividend YieldN/A1.85%5.69%4.61%P/E RatioN/A21.1374.5925.92Price / SalesN/A31.03449.5483.33Price / CashN/A24.7237.0859.91Price / Book0.573.5212.156.29Net Income-$44.58M$210.50M$3.28B$270.85M7 Day Performance2.01%-0.18%0.98%3.36%1 Month Performance10.20%3.91%7.20%6.41%1 Year Performance-91.97%-10.02%63.06%28.26% Cellectar Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLRBCellectar Biosciences3.3217 of 5 stars$5.08-3.8%$375.00+7,281.9%-91.6%$16.85MN/A0.0010Short Interest ↓MNOVMediciNova2.3735 of 5 stars$1.26-2.3%$7.00+455.6%-36.2%$63.27M$134.60K-5.0410GANXGain Therapeutics2.6007 of 5 stars$1.75-0.6%$8.00+357.1%+15.4%$63.27M$50K-2.7820ABVCABVC BioPharma0.6982 of 5 stars$2.72+2.6%N/A+303.2%$62.39M$510K-16.0030IMMXImmix Biopharma2.965 of 5 stars$2.17+0.9%$7.00+222.6%+19.4%$61.99MN/A-2.829News CoverageAnalyst ForecastShort Interest ↑HOWLWerewolf Therapeutics3.9773 of 5 stars$1.33-1.5%$8.00+501.5%-36.2%$61.73M$1.88M-0.8140BTAIBioXcel Therapeutics4.0624 of 5 stars$4.23+11.6%$39.75+839.7%-61.4%$60.67M$2.27M-0.3390Short Interest ↑CLNNClene3.2126 of 5 stars$6.63+10.0%$33.00+397.7%+1.5%$60.24M$340K-1.76100News CoverageAnalyst ForecastHigh Trading VolumeCUECue Biopharma2.7236 of 5 stars$0.78-0.4%N/A+29.9%$59.94M$9.29M-1.3960Positive NewsDTILPrecision BioSciences4.1862 of 5 stars$4.97-2.0%$47.00+845.7%-52.4%$59.76M$68.70M-0.56200News CoverageGap DownDRRXDURECT1.5187 of 5 stars$1.96+2.6%N/A+21.7%$59.31M$2.03M-19.6080News CoverageOptions Volume Related Companies and Tools Related Companies MNOV Alternatives GANX Alternatives ABVC Alternatives IMMX Alternatives HOWL Alternatives BTAI Alternatives CLNN Alternatives CUE Alternatives DTIL Alternatives DRRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLRB) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
